BCR/ABL level at 6 months identifies good...

BCR/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase

Kim, Dennis Dong Hwan, Hamad, Nada, Lee, Hong Gi, Kamel-Reid, Suzanne, Lipton, Jeffrey H.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
89
Language:
english
Journal:
American Journal of Hematology
DOI:
10.1002/ajh.23707
Date:
June, 2014
File:
PDF, 747 KB
english, 2014
Conversion to is in progress
Conversion to is failed